Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shionogi, Ping An to Set Up JV in August, Make It a Hub for China/Asia Biz
Shionogi will establish a joint venture in Shanghai next month with China’s biggest insurer Ping An Insurance under their strategic partnership deal sealed earlier this year, making the JV the base of its Chinese and Asian operations, the Osaka drug…
To read the full story
Related Article
- Shionogi to Take Full Control of 2 China Joint Ventures
December 24, 2024
- Shionogi’s Chinese JV Commences RWD Collection, Analysis of Metabolic Diseases
July 2, 2021
- Shionogi Chief Says China JV Marks Pivot from Overly US-Focused Investments
October 14, 2020
- Shionogi Hooks Up with China’s Biggest Insurance Group, Eyes RWD-Based Drug Development
March 31, 2020
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
- Gilead Files CAR-T Therapy Tecartus in Japan for MCL, B-ALL
August 21, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…